查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1463099

胃輕癱藥物市場、佔有率、規模、趨勢、行業分析報告：依藥物類別、依疾病類別、依最終用戶、依地區、依細分市場、預測，2024-2032 年

Gastroparesis Drugs Market Share, Size, Trends, Industry Analysis Report, By Drug Class (Prokinetic Agents, Antiemetic Agents, and Botulinum Toxin Injections); By Disease Class; By End User; By Region; Segment Forecast, 2024- 2032
出版日期: | 出版商: Polaris Market Research | 英文 118 Pages | 商品交期: 最快1-2個工作天內

價格

根據Polaris Market Research的最新研究，預計到2032年全球胃輕癱藥物市場規模將達到66.6235億美元。 該研究報告提供了對當前市場動態的詳細洞察，並對未來市場成長進行了分析。

由於需求增加和市場擴張的多種因素，全球胃輕癱藥物市場正在穩步成長。 胃輕癱的特徵是胃排空延遲，給受影響的人帶來了重大課題，導致噁心、嘔吐、腹脹和腹部不適等症狀。 隨著醫療保健專業人員和患者對這種疾病的認識不斷提高，對有效治療的需求持續增長，並推動胃輕癱藥物市場向前發展。

胃輕癱藥物市場成長的主要驅動力之一是胃腸道疾病（包括胃輕癱）的盛行率不斷增加。 由於飲食習慣、久坐生活方式的改變和糖尿病盛行率的增加，胃輕癱的盛行率在全球範圍內呈上升趨勢。 患者數量的迅速增加為製藥公司開發和商業化新藥創造了巨大的市場機會，以滿足這些患者未滿足的醫療需求。 此外，人口老化，特別是在已開發地區，也導致患者數量增加，進一步推動市場成長。

此外，醫療技術和藥物開發的進步正在促使胃輕癱創新療法的引入。 製藥公司大力投資研發活動，以發現和開發具有更高功效和安全性的新藥。 這些努力的結果是，出現了新型治療劑，包括促胃動力劑、止吐劑和針對涉及胃動力障礙的特定途徑的藥物。 多樣化的治療選擇為醫療保健提供者提供了更多選擇，可以根據患者的個人需求量身定制治療，從而推動市場成長。

胃輕癱治療藥物市場報告重點

促動力藥物細分市場在 2023 年佔了顯著佔有率，因為它能夠促進胃部肌肉的收縮和運動。

2023年，糖尿病性胃輕癱細分市場所佔佔有率最大，這是由於人們生活方式和消費模式的變化導致糖尿病的顯著盛行率。

由於零售藥房連鎖店的大幅擴張和患者獲取便利，預計藥房行業在預測期內將以最快的速度增長。

由於糖尿病盛行率上升和先進的醫療基礎設施的存在，北美將在 2023 年主導全球市場

主要市場參與者包括 Medtronic Plc、Rhythm Pharmaceuticals、Vanda Pharmaceuticals、Abbott Laboratories、AbbVie Inc. 和 Pfizer Inc.。

目錄

第一章簡介

第 2 章執行摘要

第三章研究方法

第四章全球胃輕癱藥物市場洞察

  • 胃輕癱藥物市場 - 最終用戶快照
  • 胃輕癱藥物市場動態
    • 推動者和機會
      • 糖尿病和老年人口的增加推動市場成長
      • 監管部門批准用於治療胃輕癱的新藥將推動市場成長。
    • 抑制因素和課題
      • 缺乏新的治療方案和限製成長的監管障礙
  • PESTEL 分析
  • 胃輕癱治療藥物市場最終使用者趨勢
  • 價值鏈分析
  • 新冠肺炎 (COVID-19) 影響分析

第 5 章依疾病類別劃分的全球市場

  • 主要發現
  • 簡介
  • 糖尿病胃輕癱
  • 特發性胃輕癱
  • 術後胃輕癱
  • 其他

第 6 章依藥物類別劃分的世界市場

  • 主要發現
  • 簡介
  • 胃腸動力促進劑
  • 止吐藥
  • 肉毒桿菌注射

第 7 章最終用戶的全球市場

  • 主要發現
  • 簡介
  • 醫院
  • 藥房
  • 診所
  • 電子商務

第 8 章依地區劃分的世界市場

  • 主要發現
  • 簡介
    • 胃輕癱治療藥物市場評估，地區，2019-2032
  • 胃輕癱藥物市場 - 北美
    • 北美：2019-2032 年胃輕癱藥物市場（依疾病分類）
    • 北美：胃輕癱藥物市場，依最終用戶劃分，2019-2032 年
    • 北美：2019-2032 年胃輕癱藥物市場（依藥物分類）
    • 胃輕癱藥物市場 - 美國
    • 胃輕癱藥物市場 - 加拿大
  • 胃輕癱藥物市場 - 歐洲
    • 歐洲：胃輕癱藥物市場，依疾病類別，2019-2032 年
    • 歐洲：胃輕癱藥物市場，依最終使用者劃分，2019-2032 年
    • 歐洲：胃輕癱藥物市場，依藥物類別，2019-2032 年
    • 胃輕癱藥物市場 - 英國
    • 胃輕癱藥物市場 - 法國
    • 胃輕癱藥物市場 - 德國
    • 胃輕癱藥物市場 - 義大利
    • 胃輕癱藥物市場 - 西班牙
    • 胃輕癱藥物市場 - 荷蘭
    • 胃輕癱藥物市場 - 俄羅斯
  • 胃輕癱藥物市場 - 亞太地區
    • 亞太地區：胃輕癱藥物市場，依疾病類別，2019-2032 年
    • 亞太地區：胃輕癱藥物市場，依最終使用者劃分，2019-2032 年
    • 亞太地區：胃輕癱藥物市場，依藥物類別，2019-2032 年
    • 胃輕癱治療藥物市場 - 中國
    • 胃輕癱藥物市場 - 印度
    • 胃輕癱藥物市場 - 馬來西亞
    • 胃輕癱治療藥物市場 - 日本
    • 胃輕癱治療藥物市場 - 印度尼西亞
    • 胃輕癱治療藥物市場 - 韓國
  • 胃輕癱藥物市場 - 中東和非洲
    • 中東和非洲：2019-2032 年胃輕癱藥物市場（依疾病類別）
    • 中東和非洲：胃輕癱藥物市場，依最終用戶劃分，2019-2032 年
    • 中東和非洲：2019-2032 年胃輕癱藥物市場（依藥物類別）
    • 胃輕癱藥物市場 - 沙烏地阿拉伯
    • 胃輕癱治療藥物市場 - 阿聯酋
    • 胃輕癱藥物市場 - 以色列
    • 胃輕癱藥物市場 - 南非
  • 胃輕癱藥物市場 - 拉丁美洲
    • 拉丁美洲：胃輕癱藥物市場，依疾病類別，2019-2032 年
    • 拉丁美洲：胃輕癱藥物市場，依最終用戶劃分，2019-2032 年
    • 拉丁美洲：2019-2032 年胃輕癱藥物市場（依藥物類別）
    • 胃輕癱藥物市場 - 墨西哥
    • 胃輕癱藥物市場 - 巴西
    • 胃輕癱藥物市場 - 阿根廷

第九章競爭態勢

  • 擴張與收購分析
    • 放大
    • 收購
  • 合作/協作/合約/出版物

第十章公司簡介

  • Abbott Laboratories（US）
  • AbbVie Inc.（US）
  • Allergan Inc.（US）
  • Evoke Pharma（US）
  • Medtronic Plc（Ireland）
  • Neurogastrx Inc.（US）
  • Pfizer Inc.（US）
  • Rhythm Pharmaceuticals Inc.（US）
  • Salix Pharmaceuticals（US）
  • TEVA Pharmaceutical（Israel）
  • Vanda Pharmaceuticals Inc.（US）
Product Code: PM4776

The global gastroparesis drugs market size is expected to reach USD 6,662.35 Million by 2032, according to a new study by Polaris Market Research. The report "Gastroparesis Drugs Market Share, Size, Trends, Industry Analysis Report, By Drug Class (Prokinetic Agents, Antiemetic Agents, and Botulinum Toxin Injections); By Disease Class; By End User; By Region; Segment Forecast, 2024 - 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The gastroparesis drugs market has been experiencing steady growth globally, driven by several factors contributing to increased demand and market expansion. Gastroparesis, a condition characterized by delayed emptying of the stomach, poses significant challenges for affected individuals, leading to symptoms such as nausea, vomiting, bloating, and abdominal discomfort. As awareness about this condition grows among healthcare professionals and patients alike, the demand for effective treatments continues to rise, propelling the gastroparesis drugs market forward.

One of the primary driving factors behind the growth of the gastroparesis drugs market is the increasing prevalence of gastrointestinal disorders, including gastroparesis. With changing dietary habits, sedentary lifestyles, and rising incidences of diabetes, the incidence of gastroparesis is on the rise globally. This surge in patient numbers has created a substantial market opportunity for pharmaceutical companies to develop and commercialize novel drugs catering to the unmet medical needs of these individuals. Moreover, the aging population, particularly in developed regions, contributes to the growing patient pool, further boosting market growth.

Furthermore, advancements in medical technology and drug development have led to the introduction of innovative treatment options for gastroparesis. Pharmaceutical companies are investing significantly in research and development activities to discover and develop new drugs with improved efficacy and safety profiles. These efforts have resulted in the emergence of novel therapeutic agents, including prokinetic agents, antiemetics, and other drugs targeting specific pathways involved in gastric motility disorders. The availability of a diverse range of treatment options provides healthcare providers with more choices to tailor therapy according to individual patient needs, thereby driving market growth.

Gastroparesis Drugs Market Report Highlights

Prokinetic agents segment accounted for noteworthy share in 2023, that is due to its ability to boost stomach muscles contractions and movement

Diabetic gastroparesis segment held the maximum share in 2023, owing to significant prevalence of diabetes due to change in people lifestyle and consumption patterns

Pharmacies segment will grow at highest pace during forecast period, that is attributed to significant expansion of retail pharmacy chains and easy accessibility to patients

North America dominated the global market in 2023, on account of rising prevalence of diabetes and presence of advanced healthcare infrastructure

The key market players include Medtronic Plc, Rhythm Pharmaceuticals, Vanda Pharmaceuticals, Abbott Laboratories, AbbVie Inc., and Pfizer Inc.

Polaris Market Research has segmented the gastroparesis drugs market report based on drug class, disease class, end user, and region:

Gastroparesis Drugs, Drug Class Outlook (Revenue - USD Million, 2023 - 2032)

  • Prokinetic Agents
  • Antiemetic Agents
  • Botulinum Toxin Injections

Gastroparesis Drugs, Disease Class Outlook (Revenue - USD Million, 2023 - 2032)

  • Diabetic Gastroparesis
  • Idiopathic Gastroparesis
  • Post-surgical Gastroparesis
  • Others

Gastroparesis Drugs, End User Outlook (Revenue - USD Million, 2023 - 2032)

  • Hospitals
  • Pharmacies
  • Clinics
  • E-commerce

Gastroparesis Drugs, Regional Outlook (Revenue - USD Million, 2023 - 2032)

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Netherlands
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Malaysia
  • Latin America
  • Argentina
  • Brazil
  • Mexico
  • Middle East & Africa
  • UAE
  • Saudi Arabia
  • Israel
  • South Africa

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Gastroparesis Drugs Market Insights

  • 4.1. Gastroparesis Drugs Market - End User Snapshot
  • 4.2. Gastroparesis Drugs Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Rising prevalence of diabetes and geriatric population to boost market growth
      • 4.2.1.2. Regulatory approvals for new drugs for gastroparesis treatment to boost market growth.
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. Lack of novel treatment options and regulatory hurdles to restrain growth
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTEL Analysis
  • 4.5. Gastroparesis Drugs Market End User Trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Gastroparesis Drugs Market, by Disease Class

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
  • 5.3. Diabetic Gastroparesis
    • 5.3.1. Global Gastroparesis Drugs Market, by Diabetic Gastroparesis, by Region, 2019-2032 (USD Million)
  • 5.4. Idiopathic Gastroparesis
    • 5.4.1. Global Gastroparesis Drugs Market, by Idiopathic Gastroparesis, by Region, 2019-2032 (USD Million)
  • 5.5. Post-surgical Gastroparesis
    • 5.5.1. Global Gastroparesis Drugs Market, by Post-surgical Gastroparesis, by Region, 2019-2032 (USD Million)
  • 5.6. Others
    • 5.6.1. Global Gastroparesis Drugs Market, by Others, by Region, 2019-2032 (USD Million)

6. Global Gastroparesis Drugs Market, by Drug Class

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
  • 6.3. Prokinetic Agents
    • 6.3.1. Global Gastroparesis Drugs Market, by Prokinetic Agents, by Region, 2019-2032 (USD Million)
  • 6.4. Antiemetic Agents
    • 6.4.1. Global Gastroparesis Drugs Market, by Antiemetic Agents, by Region, 2019-2032 (USD Million)
  • 6.5. Botulinum Toxin Injections
    • 6.5.1. Global Gastroparesis Drugs Market, by Botulinum Toxin Injections, by Region, 2019-2032 (USD Million)

7. Global Gastroparesis Drugs Market, by End User

  • 7.1. Key Findings
  • 7.2. Introduction
    • 7.2.1. Global Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
  • 7.3. Hospitals
    • 7.3.1. Global Gastroparesis Drugs Market, by Hospitals, By Region, 2019-2032 (USD Million)
  • 7.4. Pharmacies
    • 7.4.1. Global Gastroparesis Drugs Market, by Pharmacies, By Region, 2019-2032 (USD Million)
  • 7.5. Clinics
    • 7.5.1. Global Gastroparesis Drugs Market, by Clinics, By Region, 2019-2032 (USD Million)
  • 7.6. E-commerce
    • 7.6.1. Global Gastroparesis Drugs Market, by E-commerce, By Region, 2019-2032 (USD Million)

8. Global Gastroparesis Drugs Market, by Geography

  • 8.1. Key findings
  • 8.2. Introduction
    • 8.2.1. Gastroparesis Drugs Market Assessment, By Geography, 2019-2032 (USD Million)
  • 8.3. Gastroparesis Drugs Market - North America
    • 8.3.1. North America: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
    • 8.3.2. North America: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
    • 8.3.3. North America: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
    • 8.3.4. Gastroparesis Drugs Market - U.S.
      • 8.3.4.1. U.S.: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
      • 8.3.4.2. U.S.: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
      • 8.3.4.3. U.S.: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
    • 8.3.5. Gastroparesis Drugs Market - Canada
      • 8.3.5.1. Canada: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
      • 8.3.5.2. Canada.: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
      • 8.3.5.3. Canada: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
  • 8.4. Gastroparesis Drugs Market - Europe
    • 8.4.1. Europe: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
    • 8.4.2. Europe.: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
    • 8.4.3. Europe: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
    • 8.4.4. Gastroparesis Drugs Market - UK
      • 8.4.4.1. UK: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
      • 8.4.4.2. UK.: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
      • 8.4.4.3. UK: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
    • 8.4.5. Gastroparesis Drugs Market - France
      • 8.4.5.1. France: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
      • 8.4.5.2. France.: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
      • 8.4.5.3. France: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
    • 8.4.6. Gastroparesis Drugs Market - Germany
      • 8.4.6.1. Germany: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
      • 8.4.6.2. Germany.: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
      • 8.4.6.3. Germany: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
    • 8.4.7. Gastroparesis Drugs Market - Italy
      • 8.4.7.1. Italy: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
      • 8.4.7.2. Italy.: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
      • 8.4.7.3. Italy: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
    • 8.4.8. Gastroparesis Drugs Market - Spain
      • 8.4.8.1. Spain: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
      • 8.4.8.2. Spain.: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
      • 8.4.8.3. Spain: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
    • 8.4.9. Gastroparesis Drugs Market - Netherlands
      • 8.4.9.1. Netherlands: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
      • 8.4.9.2. Netherlands.: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
      • 8.4.9.3. Netherlands: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
    • 8.4.10. Gastroparesis Drugs Market - Russia
      • 8.4.10.1. Russia: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
      • 8.4.10.2. Russia.: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
      • 8.4.10.3. Russia: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
  • 8.5. Gastroparesis Drugs Market - Asia Pacific
    • 8.5.1. Asia Pacific: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
    • 8.5.2. Asia Pacific.: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
    • 8.5.3. Asia Pacific: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
    • 8.5.4. Gastroparesis Drugs Market - China
      • 8.5.4.1. China: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
      • 8.5.4.2. China.: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
      • 8.5.4.3. China: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
    • 8.5.5. Gastroparesis Drugs Market - India
      • 8.5.5.1. India: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
      • 8.5.5.2. India.: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
      • 8.5.5.3. India: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
    • 8.5.6. Gastroparesis Drugs Market - Malaysia
      • 8.5.6.1. Malaysia: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
      • 8.5.6.2. Malaysia.: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
      • 8.5.6.3. Malaysia: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
    • 8.5.7. Gastroparesis Drugs Market - Japan
      • 8.5.7.1. Japan: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
      • 8.5.7.2. Japan.: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
      • 8.5.7.3. Japan: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
    • 8.5.8. Gastroparesis Drugs Market - Indonesia
      • 8.5.8.1. Indonesia: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
      • 8.5.8.2. Indonesia.: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
      • 8.5.8.3. Indonesia: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
    • 8.5.9. Gastroparesis Drugs Market - South Korea
      • 8.5.9.1. South Korea: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
      • 8.5.9.2. South Korea.: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
      • 8.5.9.3. South Korea: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
  • 8.6. Gastroparesis Drugs Market - Middle East & Africa
    • 8.6.1. Middle East & Africa: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
    • 8.6.2. Middle East & Africa.: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
    • 8.6.3. Middle East & Africa: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
    • 8.6.4. Gastroparesis Drugs Market - Saudi Arabia
      • 8.6.4.1. Saudi Arabia: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
      • 8.6.4.2. Saudi Arabia.: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
      • 8.6.4.3. Saudi Arabia: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
    • 8.6.5. Gastroparesis Drugs Market - UAE
      • 8.6.5.1. UAE: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
      • 8.6.5.2. UAE.: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
      • 8.6.5.3. UAE: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
    • 8.6.6. Gastroparesis Drugs Market - Israel
      • 8.6.6.1. Israel: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
      • 8.6.6.2. Israel.: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
      • 8.6.6.3. Israel: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
    • 8.6.7. Gastroparesis Drugs Market - South Africa
      • 8.6.7.1. South Africa: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
      • 8.6.7.2. South Africa.: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
      • 8.6.7.3. South Africa: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
  • 8.7. Gastroparesis Drugs Market - Latin America
    • 8.7.1. Latin America: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
    • 8.7.2. Latin America.: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
    • 8.7.3. Latin America: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
    • 8.7.4. Gastroparesis Drugs Market - Mexico
      • 8.7.4.1. Mexico: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
      • 8.7.4.2. Mexico.: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
      • 8.7.4.3. Mexico: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
    • 8.7.5. Gastroparesis Drugs Market - Brazil
      • 8.7.5.1. Brazil: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
      • 8.7.5.2. Brazil.: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
      • 8.7.5.3. Brazil: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
    • 8.7.6. Gastroparesis Drugs Market - Argentina
      • 8.7.6.1. Argentina: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
      • 8.7.6.2. Argentina.: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
      • 8.7.6.3. Argentina: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)

9. Competitive Landscape

  • 9.1. Expansion and Acquisition Analysis
    • 9.1.1. Expansion
    • 9.1.2. Acquisitions
  • 9.2. Partnerships/Collaborations/Agreements/Exhibitions

10. Company Profiles

  • 10.1. Abbott Laboratories (US)
    • 10.1.1. Company Overview
    • 10.1.2. Financial Performance
    • 10.1.3. Product Benchmarking
    • 10.1.4. Recent Development
  • 10.2. AbbVie Inc. (US)
    • 10.2.1. Company Overview
    • 10.2.2. Financial Performance
    • 10.2.3. Product Benchmarking
    • 10.2.4. Recent Development
  • 10.3. Allergan Inc. (US)
    • 10.3.1. Company Overview
    • 10.3.2. Financial Performance
    • 10.3.3. Product Benchmarking
    • 10.3.4. Recent Development
  • 10.4. Evoke Pharma (US)
    • 10.4.1. Company Overview
    • 10.4.2. Financial Performance
    • 10.4.3. Product Benchmarking
    • 10.4.4. Recent Development
  • 10.5. Medtronic Plc (Ireland)
    • 10.5.1. Company Overview
    • 10.5.2. Financial Performance
    • 10.5.3. Product Benchmarking
    • 10.5.4. Recent Development
  • 10.6. Neurogastrx Inc. (US)
    • 10.6.1. Company Overview
    • 10.6.2. Financial Performance
    • 10.6.3. Product Benchmarking
    • 10.6.4. Recent Development
  • 10.7. Pfizer Inc. (US)
    • 10.7.1. Company Overview
    • 10.7.2. Financial Performance
    • 10.7.3. Product Benchmarking
    • 10.7.4. Recent Development
  • 10.8. Rhythm Pharmaceuticals Inc. (US)
    • 10.8.1. Company Overview
    • 10.8.2. Financial Performance
    • 10.8.3. Product Benchmarking
    • 10.8.4. Recent Development
  • 10.9. Salix Pharmaceuticals (US)
    • 10.9.1. Company Overview
    • 10.9.2. Financial Performance
    • 10.9.3. Product Benchmarking
    • 10.9.4. Recent Development
  • 10.10. TEVA Pharmaceutical (Israel)
    • 10.10.1. Company Overview
    • 10.10.2. Financial Performance
    • 10.10.3. Product Benchmarking
    • 10.10.4. Recent Development
  • 10.11. Vanda Pharmaceuticals Inc. (US)
    • 10.11.1. Company Overview
    • 10.11.2. Financial Performance
    • 10.11.3. Product Benchmarking
    • 10.11.4. Recent Development

List of Tables

  • Table 1 Global Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
  • Table 2 Global Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
  • Table 3 Global Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
  • Table 4 Gastroparesis Drugs Market Assessment, By Geography, 2019-2032 (USD Million)
  • Table 5 North America: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
  • Table 6 North America: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
  • Table 7 North America: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
  • Table 8 U.S.: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
  • Table 9 U.S.: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
  • Table 10 U.S.: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
  • Table 11 Canada: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
  • Table 12 Canada: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
  • Table 13 Canada: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
  • Table 14 Europe: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
  • Table 15 Europe: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
  • Table 16 Europe: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
  • Table 17 UK: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
  • Table 18 UK: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
  • Table 19 UK: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
  • Table 20 France: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
  • Table 21 France: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
  • Table 22 France: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
  • Table 23 Germany: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
  • Table 24 Germany: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
  • Table 25 Germany: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
  • Table 26 Italy: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
  • Table 27 Italy: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
  • Table 28 Italy: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
  • Table 29 Spain: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
  • Table 30 Spain: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
  • Table 31 Spain: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
  • Table 32 Netherlands: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
  • Table 33 Netherlands: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
  • Table 34 Netherlands: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
  • Table 35 Russia: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
  • Table 36 Russia: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
  • Table 37 Russia: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
  • Table 38 Asia Pacific: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
  • Table 39 Asia Pacific: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
  • Table 40 Asia Pacific: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
  • Table 41 China: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
  • Table 42 China: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
  • Table 43 China: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
  • Table 44 India: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
  • Table 45 India: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
  • Table 46 India: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
  • Table 47 Malaysia: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
  • Table 48 Malaysia: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
  • Table 49 Malaysia: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
  • Table 50 Japan: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
  • Table 51 Japan: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
  • Table 52 Japan: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
  • Table 53 Indonesia: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
  • Table 54 Indonesia: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
  • Table 55 Indonesia: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
  • Table 56 South Korea: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
  • Table 57 South Korea: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
  • Table 58 South Korea: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
  • Table 59 Middle East & Africa: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
  • Table 60 Middle East & Africa: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
  • Table 61 Middle East & Africa: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
  • Table 62 Saudi Arabia: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
  • Table 63 Saudi Arabia: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
  • Table 64 Saudi Arabia: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
  • Table 65 UAE: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
  • Table 66 UAE: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
  • Table 67 UAE: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
  • Table 68 Israel: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
  • Table 69 Israel: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
  • Table 70 Israel: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
  • Table 71 South Africa: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
  • Table 72 South Africa: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
  • Table 73 South Africa: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
  • Table 74 Latin America: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
  • Table 75 Latin America: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
  • Table 76 Latin America: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
  • Table 77 Mexico: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
  • Table 78 Mexico: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
  • Table 79 Mexico: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
  • Table 80 Brazil: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
  • Table 81 Brazil: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
  • Table 82 Brazil: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
  • Table 83 Argentina: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
  • Table 84 Argentina: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
  • Table 85 Argentina: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)

List of Figures

  • Figure 1. Global Gastroparesis Drugs Market, 2019-2032 (USD Million)
  • Figure 2. Integrated Ecosystem
  • Figure 3. Research Methodology: Top-Down & Bottom-Up Approach
  • Figure 4. Market by Geography
  • Figure 5. Porter's Five Forces
  • Figure 6. Market by Drug Class
  • Figure 7. Global Gastroparesis Drugs Market, by Drug Class, 2022 & 2032 (USD Million)
  • Figure 8. Market by Disease Class
  • Figure 9. Global Gastroparesis Drugs Market, by Disease Class, 2022 & 2032 (USD Million)
  • Figure 10. Market by End User
  • Figure 11. Global Gastroparesis Drugs Market, by End User, 2022 & 2032 (USD Million)
  • Figure 12. Gastroparesis Drugs Market Assessment, By Geography, 2019-2032 (USD Million)
  • Figure 13. Strategic Analysis - Gastroparesis Drugs Market